Merck & Co., Inc. (NYSE:MRK) Shares Acquired by Rench Wealth Management Inc.

Rench Wealth Management Inc. boosted its stake in shares of Merck & Co., Inc. (NYSE:MRKGet Rating) by 0.4% in the fourth quarter, according to its most recent filing with the Securities and Exchange Commission (SEC). The firm owned 64,028 shares of the company’s stock after purchasing an additional 277 shares during the quarter. Merck & Co., Inc. makes up approximately 2.2% of Rench Wealth Management Inc.’s holdings, making the stock its 20th largest position. Rench Wealth Management Inc.’s holdings in Merck & Co., Inc. were worth $4,907,000 at the end of the most recent reporting period.

A number of other large investors also recently added to or reduced their stakes in MRK. Financial Avengers Inc. boosted its position in Merck & Co., Inc. by 115.8% during the 4th quarter. Financial Avengers Inc. now owns 328 shares of the company’s stock valued at $25,000 after purchasing an additional 176 shares during the period. Moisand Fitzgerald Tamayo LLC boosted its position in Merck & Co., Inc. by 78.0% during the 4th quarter. Moisand Fitzgerald Tamayo LLC now owns 356 shares of the company’s stock worth $27,000 after acquiring an additional 156 shares during the period. Retirement Group LLC boosted its position in Merck & Co., Inc. by 116.4% during the 3rd quarter. Retirement Group LLC now owns 608 shares of the company’s stock worth $30,000 after acquiring an additional 327 shares during the period. Steward Financial Group LLC acquired a new position in Merck & Co., Inc. during the 4th quarter worth $40,000. Finally, Ritter Daniher Financial Advisory LLC boosted its position in Merck & Co., Inc. by 33.9% during the 4th quarter. Ritter Daniher Financial Advisory LLC now owns 517 shares of the company’s stock worth $40,000 after acquiring an additional 131 shares during the period. Institutional investors and hedge funds own 72.88% of the company’s stock.

A number of research analysts have issued reports on MRK shares. Mizuho started coverage on Merck & Co., Inc. in a research report on Friday, April 1st. They set a “buy” rating and a $100.00 price target for the company. SVB Leerink reduced their price target on Merck & Co., Inc. from $100.00 to $97.00 and set an “outperform” rating for the company in a research report on Thursday, April 21st. Morgan Stanley reduced their price target on Merck & Co., Inc. from $82.00 to $80.00 and set an “equal weight” rating for the company in a research report on Wednesday, April 6th. Barclays upped their price objective on Merck & Co., Inc. from $94.00 to $97.00 and gave the company an “overweight” rating in a report on Tuesday, April 12th. Finally, JPMorgan Chase & Co. cut their price objective on Merck & Co., Inc. from $100.00 to $95.00 and set an “overweight” rating for the company in a report on Friday, January 28th. Eight equities research analysts have rated the stock with a hold rating, seven have issued a buy rating and two have issued a strong buy rating to the stock. Based on data from MarketBeat.com, the company has a consensus rating of “Buy” and an average target price of $90.69.

Shares of Merck & Co., Inc. stock traded down $0.89 on Wednesday, reaching $93.75. 10,786,810 shares of the company were exchanged, compared to its average volume of 12,169,205. The stock has a fifty day moving average price of $86.38 and a 200-day moving average price of $81.06. The firm has a market capitalization of $237.08 billion, a price-to-earnings ratio of 16.77, a price-to-earnings-growth ratio of 1.24 and a beta of 0.37. The company has a current ratio of 1.40, a quick ratio of 1.02 and a debt-to-equity ratio of 0.75. Merck & Co., Inc. has a fifty-two week low of $70.89 and a fifty-two week high of $94.92.

Merck & Co., Inc. (NYSE:MRKGet Rating) last announced its earnings results on Thursday, April 28th. The company reported $2.14 earnings per share (EPS) for the quarter, topping analysts’ consensus estimates of $1.83 by $0.31. The company had revenue of $15.90 billion for the quarter, compared to analyst estimates of $14.64 billion. Merck & Co., Inc. had a return on equity of 47.86% and a net margin of 26.27%. Merck & Co., Inc.’s revenue for the quarter was up 31.6% compared to the same quarter last year. During the same period in the previous year, the firm earned $1.40 earnings per share. On average, equities analysts anticipate that Merck & Co., Inc. will post 7.31 earnings per share for the current fiscal year.

Merck & Co., Inc. Company Profile (Get Rating)

Merck & Co, Inc operates as a healthcare company worldwide. It operates through two segments, Pharmaceutical and Animal Health. The Pharmaceutical segment offers human health pharmaceutical products in the areas of oncology, hospital acute care, immunology, neuroscience, virology, cardiovascular, and diabetes, as well as vaccine products, such as preventive pediatric, adolescent, and adult vaccines.

Featured Stories

Institutional Ownership by Quarter for Merck & Co., Inc. (NYSE:MRK)

Receive News & Ratings for Merck & Co. Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Merck & Co. Inc. and related companies with MarketBeat.com's FREE daily email newsletter.